Atlas FDA

AeroPace® System

FDA premarket approval P240012/S001 · decided 2025-01-30

Approval details

PMA number
P240012
Supplement
S001
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Postapproval Study Protocol
Trade name
AeroPace® System
Generic name
Transvenous temporary phrenic nerve stimulator
Applicant
Lungpacer Medical USA, Inc.
Date received
2024-12-31
Decision date
2025-01-30
Days to decision
30 days
Decision code
APPR
Product code
SDL
Advisory committee
Anesthesiology
Expedited review
No
Location
Exton, PA
Statement
Approval of the protocol for the post-approval study AERO-PAS.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.